Aperture Investors LLC Cuts Stock Holdings in Rxo Inc $RXO

Aperture Investors LLC reduced its stake in Rxo Inc (NYSE:RXO) by 49.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 50,606 shares of the company’s stock after selling 48,955 shares during the period. Aperture Investors LLC’s holdings in RXO were worth $796,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of RXO. Geneos Wealth Management Inc. purchased a new position in shares of RXO during the first quarter valued at about $30,000. AlphaQuest LLC purchased a new stake in shares of RXO in the second quarter worth about $29,000. Thurston Springer Miller Herd & Titak Inc. boosted its stake in RXO by 25.1% during the second quarter. Thurston Springer Miller Herd & Titak Inc. now owns 3,433 shares of the company’s stock valued at $54,000 after buying an additional 688 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in RXO by 34.1% during the second quarter. Nisa Investment Advisors LLC now owns 4,576 shares of the company’s stock valued at $72,000 after buying an additional 1,163 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in RXO during the 1st quarter valued at approximately $97,000. Hedge funds and other institutional investors own 92.73% of the company’s stock.

RXO Trading Up 3.1%

Shares of RXO opened at $14.56 on Wednesday. Rxo Inc has a twelve month low of $10.43 and a twelve month high of $29.60. The company has a market cap of $2.39 billion, a P/E ratio of -33.86 and a beta of 1.74. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 0.24. The company’s fifty day simple moving average is $15.01 and its 200-day simple moving average is $15.67.

RXO (NYSE:RXO) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.44 billion. RXO had a positive return on equity of 0.88% and a negative net margin of 1.25%.RXO’s revenue for the quarter was up 34.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.05 earnings per share. As a group, analysts expect that Rxo Inc will post 0.31 EPS for the current year.

Insider Buying and Selling at RXO

In other RXO news, CEO Andrew M. Wilkerson purchased 7,775 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average cost of $12.88 per share, with a total value of $100,142.00. Following the purchase, the chief executive officer owned 7,775 shares of the company’s stock, valued at approximately $100,142. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas A. Szlosek acquired 20,308 shares of the company’s stock in a transaction that occurred on Friday, November 7th. The shares were acquired at an average price of $12.37 per share, with a total value of $251,209.96. Following the acquisition, the director owned 36,508 shares in the company, valued at $451,603.96. This trade represents a 125.36% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 40,250 shares of company stock worth $488,875 over the last 90 days. Company insiders own 1.48% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on RXO. Morgan Stanley raised RXO from an “equal weight” rating to an “overweight” rating and set a $19.00 price objective on the stock in a report on Tuesday, November 11th. JPMorgan Chase & Co. boosted their price target on shares of RXO from $15.00 to $16.00 and gave the stock an “underweight” rating in a research report on Wednesday, October 8th. Benchmark reaffirmed a “hold” rating on shares of RXO in a research note on Wednesday, October 22nd. Barclays lowered their price objective on shares of RXO from $17.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of RXO in a research note on Monday, November 24th. Four investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, RXO presently has an average rating of “Hold” and an average target price of $16.69.

RXO Profile

RXO, Inc provides full truckload freight transportation brokering services. It also offers brokered services for managed transportation, last mile, and freight forwarding. The company was incorporated in 2022 and is based in Charlotte, North Carolina.